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Summary
Background The safety of topical therapies for atopic dermatitis (AD), a common
and morbid disease, has recently been the focus of increased scrutiny, adding
confusion as how best to manage these patients.
Objectives The objective of these systematic reviews was to determine the safety of
topical therapies for AD.
Methods Databases searched included: OVID Medline, Medline In-Process and
Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Con-
trolled Trials. In addition to the articles identified by this search, investigators
were also referred to a list of links (most recently updated 25 September 2005)
to recent Food and Drug Administration (FDA) studies, reports and meetings
regarding the topical calcineurin inhibitors for further potential references. Only
fully published papers available in English and data obtained from FDA sites were
included. Furthermore, the criteria for inclusion and exclusion for each systema-
tic review were further evaluated at a meeting of all of the content and evidence-
based medicine experts participating in this process and alteration of the
inclusion criteria was done at that time when it was felt necessary to avoid inclu-
sion of lower-quality data in the review. Qualitative review of the abstracted data
was performed and reviewed at a meeting of all of the content and evidence-
based medicine experts.
Results While systemic exposure to these topical agents does occur, physiological
changes appear to be uncommon and systemic complications rare and have only
been found with use of topical corticosteroids.
Conclusions Based on the data that are available the overall safety of AD therapies
appears to be good with the only documented systemic side-effects of therapy
those occasionally seen with use of topical corticosteroids.
Atopic dermatitis (AD) is an extremely common disease that
adversely impacts the quality of life (QoL) of affected children
and adults.1,2 The pathogenesis of AD is incompletely under-
stood, but involves dysregulation of inflammation and the
response to antigens.1,3 Modern therapy of AD has largely been
focused on agents that control perturbations in the inflamma-
tory response, i.e. anti-inflammatory and immunosuppressive
compounds. The spectrum of topical therapies used to treat AD
ranges from emollients to potent anti-inflammatory and immu-
nomodulating agents including topical corticosteroids (TS), a
class of compounds with a broad effect on immune regulatory
functions, and topical calcineurin inhibitors (TCI), more
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recently developed compounds with a more selective effect on
immunoregulation.4 These topical treatments for AD, while
effective in controlling disease activity and maintaining clinical
remission, may also occasionally be associated with local
adverse reactions including infection.5,6 Furthermore, use of
these potent topical anti-inflammatory and immunomodulating
drugs can result in absorption and systemic drug exposure and
thus use of TS and TCI has the potential to result in systemic
side-effects and/or complications which accompany immuno-
suppression.7–11
In order to address what is known about the safety of topi-
cal therapies for AD, as well as to identify areas of unmet need
in this field, a series of systematic reviews was conducted.
Materials and methods
The following seven focused clinical questions were formu-
lated following extensive discussions among the authors of
this paper who are experts in dermatology, AD and/or evi-
dence-based medicine. These authors identified the following
key issues that needed to be addressed when attempting to
evaluate the safety of therapies for AD.
1 What is the burden of illness of AD, including the preva-
lence of AD and the effect AD has on QoL?
2 What is the postulated pathophysiology of AD and what
are the mechanism(s) of action of topical therapies for AD?
3 What are the local side-effects of topical therapies for AD?
4 What are the systemic exposures of topical therapies for AD
and their effect on growth, the hypothalamic-pituitary-adrenal
(HPA) axis and other physiological processes?
5 What is the postulated mechanism for increased risk for
neoplasia in those using topical immunosuppressive therapies?
6 What is the background prevalence of neoplasia in the gen-
eral population, those with atopic disease and those receiving
topical therapy for AD?
7 What are the systemic side-effects (infection and neoplasia)
of topical therapies for AD?
Each of the above questions was then assigned to one or
more experts in that specific field of AD and an expert in per-
forming systematic reviews. Separate and specific systematic
reviews were then performed for each of the specific focused
questions (Appendix S1 in Supplementary Material).
Before developing the specific and unique search strategy
for each of these questions, search boundaries, developed by
consensus, were formulated using a defined set of treatments
for AD (Table 1). Each of the individual search strategies was
then adapted to the specific focused question after consultation
with an experienced medical librarian (K.K.), who is an expert
in performing searches for systematic reviews. Databases
searched included: OVID Medline, Medline In-Process and
Other Non-Indexed Citations, Embase, and the Cochrane Cen-
tral Register of Controlled Trials.
The titles and abstracts of identified articles for each of the
specific individual search strategies were then reviewed by the
content expert for that question. Articles thought to be relevant
were identified and subjected to more intensive review. Articles
meeting a priori inclusion criteria were then abstracted for infor-
mation pertinent to the focused question being addressed. A
hand search of references from these articles was used to iden-
tify other possible articles meeting the inclusion criteria that
were missed with the database search.
In addition to the articles identified by the search, investi-
gators were also referred to the following list of links (most
recently updated as of 25 September 2005) to recent Food
and Drug Administration (FDA) studies, reports and meetings
regarding the TCI for further potential references: Pediatric
Advisory Committee briefing information, http://www.fda.
gov/ohrms/dockets/ac/05/briefing/2005-4089b2.htm; back-
ground package from Fujisawa Healthcare Inc., http://www.
fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_02_02_
Protopic%20Fujisawa%20briefing.doc; general information on
drugs approved by the FDA, http://www.fda.gov/cder/drug/
infopage/protopic/default.htm; FDA memorandum, http://
www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4089b2_
01_01_%20Briefing%20Memo.pdf; FDA Elidel label with
background study information, http://www.fda.gov/cder/
foi/label/2004/21302s005lbl.pdf; nonclinical pharmacology/
toxicology data for Protopic, http://www.fda.gov/ohrms/
dockets/ac/00/slides/3659s1_04_hill/; FDA Pediatric Advi-
sory Subcommittee Transcripts, http://www.fda.gov/ohrms/




Only fully published papers available in English and data
from the above websites were included in the systematic
reviews. Furthermore, the criteria for inclusion and exclu-
sion for each systematic review were further evaluated at a
meeting of all of the content and evidence-based medicine
experts participating in this process. An alteration of the
inclusion criteria was done at that time when, by consen-
sus, it was felt necessary to avoid inclusion of lower-quality
data in the review.
Table 1 Topical therapies for atopic dermatitis used as search terms
for these systematic reviews





Calcineurin or calcineurin inhibitors or tacrolimus or
pimecrolimus or Protopic or Elidel or Tsukubaenolide
Cromolyn sodium or cromoglycate disodium or Altoderm
Phosphodiesterase inhibitors
Vitamin B2 or cyanocobalamin
Immunosuppressive agents or immunomodulators
Adrenal cortex hormones or corticosteroids or hydrocortisone
Dermatological agents or ointments or emollients
Ceramides
Histamine H1 antagonists
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Results
Question 1. What is the burden of illness of atopic
dermatitis?
Although this specific question was addressed through the sys-
tematic review performed, the results do not specifically deal
with safety of therapy for AD and are therefore not further
presented.
Question 2. What is the pathophysiology of atopic
dermatitis and mechanism of action of therapies for
atopic dermatitis?
Following the initial search and review of papers it became
evident that a formal systematic review process could not
address this complex question. As such the results of this
search are not presented and will not be further discussed.
Question 3. What are the local side-effects of topical
therapy for atopic dermatitis?
The search strategy identified 586 papers, of which 166
were considered potentially relevant. Further analysis of these
papers identified 61 studies meeting initial inclusion criteria
(randomized controlled trials with more than 50 subjects,
unique case reports of potential relevance, summaries or
reviews of prior studies or adverse event experiences). Addi-
tional information was obtained from data available from
package inserts, data summaries and regulatory filings with
the FDA. Skin malignancy is addressed in this section of the
review, rather than in the sections on systemic side-effects
or neoplasia risk.
Coal tar
Topical coal tar has been most extensively studied in patients
with psoriasis, and many different formulations and doses
have been used. Based on the limited data available, the
local side-effect profile has not been well characterized by
today’s standards. However, there has been no demonstrated
increase in incidence of skin cancer when compared with a
reference population.12–16 There were no prospective vehi-
cle-controlled trials of sufficient duration in patients with
AD to provide a definitive answer to the question of
whether local side-effects or skin neoplasia are increased
with the use of coal tar.
Doxepin
Studies investigating the local effects of topical doxepin have
demonstrated local side-effects (stinging and burning) both in
patients receiving active drug and in those receiving a control
vehicle; however, the use of doxepin does result in signifi-
cantly more sedation (15Æ5–28% vs. 2–2Æ5%) that is generally
mild and transient.17,18 Allergic contact dermatitis secondary
to the use of topical doxepin has been reported and is well
known; however, the specific incidence of this outcome can-
not be established with certainty based on the available
data.19–22 The incidence of cutaneous malignancy with the use
of doxepin cannot be absolutely established, but it has not
been reported in doxepin users.
Antibiotics and antiseptics
The literature is lacking with respect to robust studies in this
category. Of particular note, however, is a comprehensive
review of consolidated patch test findings performed in the
U.K. where the results in over 8500 atopic patients were com-
pared with those in over 33 000 nonatopic patients between
1995 and 1999. The incidence of local adverse events related
to topical antibiotic and antiseptic use appears to increase with
the use of neomycin sulphate and bufemac, but not bacitracin,
in those aged over 40 years and with certain preservatives
(formaldehyde, sorbic and benzoic acid, parabens) and fra-
grance.23 The incidence of local side-effects and cutaneous
malignancy with use of these agents cannot be established
given the available data.23,24
Corticosteroids
Local adverse effects of TS are known, but are poorly charac-
terized with respect to true incidence, given that evidence
from studies performed to modern-day standards is lacking
for many products. In controlled trials, secondary infection,
skin atrophy, striae, burning, itching, folliculitis, acne-like
eruptions and telangiectasia appear to be related to the use of
TS, and also appear to be potency dependent.25–31
Cases of allergic contact dermatitis with topical corticoster-
oid use have been reported and are well documented.32–36
Glaucoma is a reported finding known to be associated with
steroid use but the incidence is not well defined. Similarly,
while an association between systemic use of steroids and pos-
terior subcapsular cataract has been extensively documented,
an analysis of the literature from 1996 to 2001 yielded only
seven cases in patients receiving TS.37 Thus, there is a possi-
ble, but unsubstantiated, risk of cataracts associated with the
use of TS. Skin carcinogenicity related to the use of TS has
been a concern given known immunosuppressive effects for
this class of agents, but there are no definitive data to establish
that there is an increased risk. The approval process for newer
formulations of TS frequently required longer-term animal
carcinogenicity studies, and these studies have been unremark-
able to date.38
In summary, there are few prospective vehicle-controlled
trials of sufficient duration in patients with AD to provide a
definitive answer to the question as to the incidence of local
reactions to TS. With respect to cutaneous carcinogenicity, the
clinical data to date do not substantiate an increased risk of
cutaneous neoplasms in patients treated with TS. Limited ani-
mal carcinogenicity studies also do not support an increased
risk for these topical agents. The topic merits further investiga-
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tion before a clear evidence-based answer can be fully sub-
stantiated.
Calcineurin inhibitors
There are numerous well-designed clinical trials establishing
the incidence of local side-effects with use of TCI in
AD.8,39–55 Trials using either tacrolimus or pimecrolimus
generally demonstrate no significant differences when com-
pared with a vehicle control in the incidence of local side-
effects. Overall local side-effects commonly noted with these
agents include local cutaneous effects (e.g. erythema, pruritus
and irritation) as detailed in Tables 2 and 3. These tables
summarize the local adverse event findings from the clinical
studies submitted to the FDA to support the drug approval
for pimecrolimus and tacrolimus, respectively. The findings
also suggest that skin infections tend to be more numerous
in patients receiving TCI, although this finding is not usually
statistically significant.42–46,48,53,56,57 Although the data do
not establish a drug-related causal effect, the trend should
not be dismissed and clinicians should keep the potential
association in mind when using these agents. In general,
there seems to be a greater predilection towards virally
mediated infections as detailed in Tables 2 and 3. In a
recently published study comparing control patients with AD
vs. those treated with tacrolimus ointment, a significant
increase in infection risk was not demonstrated; however,
similar trends are noted and virally mediated infections
appear to predominate (Table 4).54 The topic merits further
investigation before a clear evidence-based answer to this
question can be fully substantiated.
Preclinical studies in animal models described in the
package inserts for tacrolimus and pimecrolimus have
demonstrated an increased risk of cutaneous malignancy
with the use of topical TCI; however, the clinical relevance
of these findings is unclear. In patients treated with pime-
crolimus and tacrolimus a small number of cutaneous
tumours has been reported to the FDA as of 30 March
2005. As of December 2004, the FDA had received 10
postmarketing reports of cases of cancer and a cancer-
related adverse event following use of pimecrolimus. Four
of the 10 cases occurred in children, three of these in chil-
dren < 6 years of age, and the other six cases occurred in
adults. Six cases described cutaneous tumours and four
described lymphomas. As of the same time point (December
2004), the FDA had received 19 postmarketing reports of
cases of cancer and a cancer-related adverse event following
use of tacrolimus. Three of the 19 cases occurred in chil-
dren up to 16 years of age, and 16 cases occurred in
adults. Nine cases described lymphomas and 10 described
cutaneous tumours, of which seven occurred at the site of
tacrolimus application, and included cases of squamous cell
carcinoma (SCC), cutaneous sarcoma, malignant melanoma
and other tumour types.58 These reports are not corrected
for the number of patients exposed to each agent nor can
the incidence of cutaneous malignancy be calculated, as the
denominator of the number of patients exposed is
unknown.
Overall, the local side-effect profile with TCI is predomi-
nantly local (burn/sting, erythema etc.) with a nonstatistically
significant trend that favours an increase in infections, espe-
cially virally mediated diseases, vs. vehicle controls. Results
Table 2 Systematic review of the local side-effects of pimecrolimus (adapted from data supplied to the Food and Drug Administration and














[n ¼ 328; n (%)]
Pimecrolimus
[n ¼ 267; n (%)]
Vehicle
[n ¼ 136; n (%)]
Pimecrolimus
[n ¼ 272; n (%)]
Vehicle
[n ¼ 75; n (%)]
Skin infection NOS 8 (3Æ0) 9 (5Æ1) 18 (5Æ4) 6 (2Æ2) 3 (4Æ0) 21 (6Æ4)
Folliculitis 3 (1Æ1) 1 (0Æ7) 3 (0Æ9) 6 (2Æ2) 3 (4Æ0) 20 (6Æ1)
Skin papilloma 1 (0Æ4) 0 2 (0Æ6) 9 (3Æ3) < 1 0
Herpes simplex 1 (0Æ04) 0 4 (1Æ2) 9 (3Æ3) 2 (2Æ7) 13 (4Æ0)
Herpes simplex
dermatitis
0 0 1 (0Æ3) 4 (1Æ5) 0 2 (0Æ6)
Application site burning 28 (10Æ4) 17 (12Æ5) 5 (1Æ5) 23 (8Æ5) 5 (6Æ7) 85 (25Æ9)
Application site reaction
NOS
8 (3Æ0) 7 (5Æ1) 7 (2Æ1) 9 (3Æ3) 2 (2Æ7) 48 (14Æ6)
Application site irritation 8 (3Æ0) 8 (5Æ9) 3 (0Æ9) 1 (0Æ4) 3 (4Æ0) 21 (6Æ4)
Application site erythema 1 (0Æ4) 0 0 6 (2Æ2) 0 7 (2Æ1)
Application site pruritus 3 (1Æ1) 2 (1Æ5) 2 (0Æ6) 5 (1Æ8) 0 18 (5Æ5)
Urticaria 3 (1Æ1) 0 1 (0Æ3) 1 (0Æ4) < 1% 3 (0Æ9)
Acne NOS 0 1 (0Æ7) 1 (0Æ3) 4 (1Æ5) < 1% 6 (1Æ8)
NOS, not otherwise specified.
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from prospective vehicle-controlled trials performed to date
demonstrate no increased malignancy risk; however, the stu-
dies are not of sufficient duration or exposure to give a defini-
tive answer regarding whether patients with AD treated with
TCI are at an increased risk of cutaneous neoplasms. The topic
merits further investigation before a clear evidence-based
answer can be fully substantiated.
In summary, local adverse events are a feature of many
topical therapies for AD, although there are few high-quality
data of sufficient duration or depth (other than for TCI and
recently approved TS) that allow quantification of the exact
incidence, or establish an incidence greater than that of a con-
trol vehicle. Finally, there are no reliable data indicating an
increased risk of cutaneous neoplasia with any topical therapy
for AD, hence this question cannot be adequately addressed
based on the existing data.
Question 4. What are the systemic exposures and
physiological effects of topical therapies for atopic
dermatitis?
The search strategy identified 682 papers and of these, 98
were considered potentially relevant when there was a men-
tion of systemic absorption either by direct plasma level mea-
surements of the compound, indirect product or metabolite,
or alteration of the HPA axis. Further analysis identified 44
meeting initial inclusion criteria – primary literature and
Table 3 Systematic review of the local side-effects of tacrolimus (adapted from data supplied to the Food and Drug Administration and obtained
via Freedom of Information Act summary basis of approval for pimecrolimus, tacrolimus)
12-week adjusted incidence rate (%)a Incidence (%)b








ointment (n ¼ 210)
0Æ1% Tacrolimus




ointment (n ¼ 118)
Skin burning 26 46 58 29 43 47 26
Pruritus 37 46 46 27 41 25 25
Skin erythema 20 25 28 13 12 12 9
Skin infection 11 12 5 14 10 11 11
Eczema herpeticum 0 1 1 0 2 2 0
Herpes simplex 4 4 4 2 0 12 5
Pustular rash 2 3 4 3 2 6 8
Folliculitis 1 6 4 0 2 11 2
Urticaria 3 3 6 1 1 5 5
Maculopapular rash 2 2 2 3 0 4 3
Rash 1 5 2 4 2 2 5
Fungal dermatitis 0 2 1 3 0 2 6
Acne 2 4 7 1 0 2 4
Sunburn 1 2 1 0 0 4 4
Skin disorder 2 2 1 1 4 1 4
Skin tingling 2 3 8 1 2 2 1
Dry skin 7 3 3 0 1 0 1
Skin neoplasm benign 1 1 1 0 0 2 3
Contact dermatitis 1 3 3 3 4 1 1
Eczema 2 2 2 0 0 3 0
Exfoliative dermatitis 3 3 1 0 0 0 2
aIn 12-week (twice daily), randomized, double-blind, parallel-group, vehicle-controlled phase III studies (in patients with atopic dermatitis;
baseline mean body surface area affected ¼ 46%).
bIn open-label studies (up to 1 year) with 0Æ1% tacrolimus ointment.
Table 4 Overall incidence (%) of infections and application site
reactions of clinical interest with tacrolimus ointment – a 4-year











Pruritus 21Æ1 19Æ4 32Æ1 26Æ3
Pustular rash 15Æ7 11Æ2 4Æ9 9Æ0
Skin burning 20Æ5 18Æ0 32Æ8 26Æ2
Skin erythema 10Æ8 5Æ8 16Æ2 12Æ3
Skin infection 22Æ7 22Æ3 15Æ2 18Æ8
Herpes simplex 4Æ3 6Æ3 7Æ1 6Æ3
Wartsa 6Æ5 7Æ3 1Æ7 4Æ3
Varicella zosterb 9Æ2 1Æ9 1Æ2 3Æ3
Molluscum contagiosuma 3Æ2 4Æ9 0 2Æ0
Eczema herpeticum 0 0Æ5 1Æ2 0Æ8
aMore common in children than in adults.
bVaricella zoster includes chicken pox and shingles.
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quantifiable assessment of systemic absorption. Additional
information was obtained from data available from package
inserts and regulatory filings with the FDA.
Coal tar
Coal tar applied topically results in measurable systemic expo-
sure to metabolites of the agent (56–380 times increase).59 The
effect of this increased systemic exposure on physiological func-
tions, such as immunosurveillance and neoplasia risk, cannot be
established based on the existing data and remains unknown.
Corticosteroids
Use of TS does result in absorption. The degree of absorption
and subsequent systemic exposure to TS is based on many fac-
tors, such as molecular structure, vehicle, dosage applied,
duration of application, use of occlusion, age of the patient,
involved body surface area, skin inflammation and inherent
metabolic differences among patients. The serum level of cor-
tisol following the administration of topical 1% hydrocorti-
sone cream varied from 47 to 961 nmol L)1 when used as a
treatment for acute AD and from 18 to 241 nmol L)1 when
used during convalescence.60 Topical use of clobetasol resulted
in peak serum levels of 0Æ6–15Æ8 ng mL)1 with associated
depression of cortisol activity for 96 h after application.61
Topical fluticasone 0Æ05% resulted in serum levels of 59–
264 pg mL)1, with two children in a multicentre study
demonstrating HPA axis suppression.62 Other studies measur-
ing the effect of TS on HPA suppression are found in Table 5.
The reported impact on growth of use of TS has been varied.
Some observational studies have reported an apparent delay in
growth and abnormal bone turnover, whereas others have
not.62–67 The effect of TS on cutaneous immunology includes
reports of decreased natural killer (NK) cell activity and inhi-
bition of Langerhans cell (LC) activity.68,69 The effect of TS
on systemic immune function and neoplasia risk remains
unknown as there are no data available regarding this issue.
Calcineurin inhibitors
Use of TCI also results in absorption and systemic exposure,
but less so than that observed with TS. Absorption of TCI,
when it occurs, appears to be in part dependent on agent and
dose as well as on area treated. Topical tacrolimus 0Æ1% has
exhibited generally low, but varied, absorption with maxi-
mum systemic concentrations usually < 5Æ0 ng mL)1 and with
most measured levels < 1 ng mL)1 in infants, children and
adults.39,42,43,70 Most published data are limited, in that often
only mean concentration is reported, not maximum concen-
tration. The highest reported level has been 9Æ5 ng mL)1 in a
child and 20 ng mL)1 in an adult.71 Available data suggest
that the bioavailability of topical tacrolimus ointment is
< 0Æ5% relative to intravenously administered tacrolimus and
< 5% of orally administered tacrolimus in patients with AD72
(Tables 6 and 7). The effect of tacrolimus on immunity has
involved measuring immune response in children receiving
pneumoccocal, tetanus and Haemophilus influenzae vaccination. No
apparent effect on these parameters of immunity was
detected.73 Topical tacrolimus used in an open-label study for
6 months or 1 year did not cause suppression of delayed-type
hypersensitivity responses, based upon recall antigen testing,
an indirect but very comprehensive measure of cellular
immune response.39
Pimecrolimus absorption also occurs, although most treated
patients have levels that are undetectable (below lower limits
of quantification).8,74,75 When compared with TS, skin con-
centrations of drug and flux are both less with topical pime-
crolimus76 although occasional patients demonstrate serum
concentrations of pimecrolimus as high as 2Æ6 ng mL)1.8
Immunologically, topical pimecrolimus induces apoptosis of
T cells without affecting LCs.68 There have been no observed
effects on B cell- or T cell-mediated vaccine responses,77 and
in a vehicle-controlled study there was no effect on skin
immune response with recall antigen testing.45 In summary,
few patients treated with TCI exhibit measurable systemic
exposure to the drug, with more patients having detectable
blood levels with tacrolimus than with pimecrolimus. How-
ever, the systemic exposure to either compound is limited,
transient in nature and far less than that observed with oral
use of these compounds.
In summary, all of the therapies for AD can result some sys-
temic exposure to the compound and thus all topical therapies
for AD have the potential for systemic-related side-effects or
toxicity. The greatest systemic exposure to a topical therapy
used for AD occurs with use of coal tar and TS. The best-docu-
mented physiological effects of systemic exposure to TS are
glucocorticoid related, with effects on the HPA axis and clinical
manifestations including adrenal suppression and insufficiency,
Cushing’s syndrome and growth retardation. Some cases have
resulted in serious outcomes, including hospitalization and
death.78 The systemic exposure demonstrated with coal tar or
TCI has not been shown to result in any significant systemic
physiological effects or toxicity based on the existing data.
Question 5. What is the postulated cause of neoplasia in
those treated with topical therapies for atopic
dermatitis?
One may consider at least three potential mechanisms by
which topical therapies may increase the risk of neoplasia in
individuals with AD: (i) direct effects of mutagenesis or geno-
toxicity, (ii) absorption of drug leading to systemic immuno-
suppression or effects on local draining lymph nodes and (iii)
local cutaneous effects leading to inhibition of immunosurveil-
lance. In addition, there may be contributions from the active
ingredient(s), the underlying condition (e.g. AD and asso-
ciated immune dysregulation and barrier compromise), as
well as a combination of any or all of these with the known
major carcinogenic effects of ultraviolet radiation. For pur-
poses of this review the focus was on the theoretical mechan-
isms of increased risk of neoplasia with use of TCI. While
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numerous TS have been available and utilized over decades for
the treatment of AD and other inflammatory skin disorders,
only the newer TCI have been more rigorously assessed for
their carcinogenic capacity. The available scientific data were
reviewed and interpreted in the context of the current under-
standing of the role of the immune system in protecting
Table 6 Systematic review of the systemic absorption of tacrolimus
Ruzicka et al.233 Alaiti et al.72 Reitamo et al.39 Patel et al.234 Harper et al.70 Stiehm et al.73
n 213 39 314 12 39 23
Age 13–60 years 5–75 years 18–70 years 7–22 months 6–12 years 2–12 years
Extent of
AD
Moderate–severe Moderate–severe 5–60% BSA Moderate–severe Moderate–severe > 10% BSA
Duration of
AD
Not known 4–12 months 2–70 years Not known Not known Not known
Strength 0Æ03%, 0Æ1% and
0Æ3% ointment
0Æ03% ointment 0Æ1% ointment 0Æ03% and
0Æ1% ointment





b.i.d. Unknown 0Æ007–0Æ016 mg kg)1 b.i.d.
Duration 3 weeks 8 days 6 or 12 months Unknown 14 days 7 weeks





















< 1 in 92%





all others < 1Æ0
at all time points
AUC Not measured Increased with larger
treatment area,
increased in facial use




AD, atopic dermatitis; BSA, involved body surface area; b.i.d., twice daily; Abs, antibodies; max, maximum; conc., concentration; LoQ,
lower quartile; AUC, area under curve.
Table 7 Systematic review of the systemic absorption of pimecrolimus
Thaci et al.74 Billich et al.76 Allen et al.8 Ling et al.75
n 13 Rat, pig, human skin 25 49
Age 20–57 years Human skin: 64, 24 years 4 months–14 years Mean 36Æ1–40Æ5
years
Severity of AD Hand eczema N/A > 10% BSA Mean 37–49%
BSA
Duration of AD 30 weeks–15 years N/A Unknown Unknown
Strength 1% cream 1% w/v 1% cream 1% cream
Amount b.i.d., dorsal and
palmar hand with occlusion





3 weeks 48 h 3 weeks 3 weeks
Test Blood levels Franz diffusion, skin strippings Blood levels Blood levels
Blood levels
(ng mL)1)
73Æ6% < LoQ (0Æ1), max
conc. ¼ 0Æ91
(day 8), 0Æ26 (day 22)
Skin conc. of same magnitude vs.




< 1 with > 50%
< LoQ (0Æ5)
95% < LoQ (0Æ5)
AUC Max AUC 0–12 ¼ 7Æ6 ng h mL)1
(day 8), decreased to 2Æ91
(day 22)
Not measured AUC 0–12 only possible to





AD, atopic dermatitis; N/A, not applicable; BSA, involved body surface area; b.i.d., twice daily; LoQ, lower quartile; max, maximum; conc.,
concentration; AUC, area under curve.
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against the development and progression of cutaneous malig-
nancy.79
In considering the potential direct carcinogenic effects of
TCI on keratinocytes, it is possible that the TCI may act as
‘initiators’ (e.g. mutagens) or ‘promoters’ (e.g. stimulators of
proliferation) of neoplasia. As part of the preclinical develop-
ment,80 both tacrolimus and pimecrolimus were assessed for
their genotoxicity in bacteria (e.g. Ames test) and mammalian
cells, as well as clastogenic (i.e. chromosomal breaking) effects
in vivo. No assay demonstrated any direct mutagenic or chro-
mosomal-damaging effects attributable to the TCI. Hence, any
carcinogenic effects attributable to TCI are much more likely
to be the result of indirect activities, e.g. suppression of the
host immune system and/or potentiation of the damaging
effects of ultraviolet radiation.
Rodent models of carcinogenicity were reviewed and
include assays with TCI given systemically, intradermally or
topically. Protocols varied from long-term, drug-only studies
to assessment of effects of TCI on photocarcinogenicity and
two-stage chemical carcinogenicity protocols. High-dose der-
mal doses of tacrolimus and pimecrolimus were both asso-
ciated with lymphoma, consistent with a systemic
immunosuppressive effect.80 Similarly, there was an associa-
tion with lymphomas for orally administered pimecrolimus at
markedly high levels, e.g. > 250 times the maximum recom-
mended human dose. There was no discernible effect on
development of cutaneous tumours for orally or dermally
administered tacrolimus or pimecrolimus. An observation was
made of benign thyroid adenomas only in a 2-year rat study
with low-dose oral pimecrolimus. This effect was not
observed in the high-dose pimecrolimus experiments. In sum-
mary, lymphomas were observed in drug-only murine proto-
cols that would be expected to result in substantially higher
systemic levels of TCI than achieved with topical use as is
done in AD, and no skin neoplasia was observed under these
conditions.
Topical administration of tacrolimus ointment and pimecro-
limus cream has also been assayed in animal models for their
effects on cutaneous photocarcinogenesis.80 An increased rate
of tumour formation was attributable to topical tacrolimus,
but not to topical pimecrolimus (curiously, an increased rate
of tumour formation was seen with the cream vehicle of the
pimecrolimus formulation). Given the thinness of murine epi-
dermis relative to human epidermis, with any increase in
photocarcinogenesis one must consider the possibility of drug
absorption and systemic immunosuppression, as opposed to
local immune effects. No attempt was made in these experi-
ments to distinguish local from systemic effects of the TCI.
The results of mouse two-stage chemical carcinogenesis stu-
dies are shown in Table 8. In this experimental system, mouse
skin is painted once with a chemical mutagen (e.g. ‘initiator’
7,12-dimethylbenz[a]anthracene), and repeatedly thereafter
with a cell activator and stimulator of proliferation (e.g. ‘pro-
moter’ 12-O-tetradecanoylphorbol-13-acetate). In one study,
when tacrolimus was applied 2 h after each application of the
promoter, papillomas were significantly increased.81 Analysis
of the draining lymph node lymphocytes revealed a substantial
alteration in T-cell counts, consistent with a systemic immu-
nosuppression or immunosuppression in the draining lymph
nodes. However, in several other studies, when either tacroli-
mus or ciclosporin was applied topically before the promoter,
there was a protective effect of the TCI against tumorigen-
esis.82–84 The apparently paradoxical effect85 of TCI protecting
against neoplasia may be explained by the fact that a role for
T cells in promoting carcinogenesis has been identified in
experimental cancer models,85–87 including two-stage chemi-
cal carcinogenesis.88 Thus, the effects that TCI may have on
promotion of cutaneous neoplasia remain to be fully eluci-
dated.
In renal transplant recipients who continually take oral cal-
cineurin inhibitors as part of a systemic immunosuppressive
regimen to prevent graft rejection, there is a clear increase in
Table 8 Mouse chemical carcinogenesis studies with topical calcineurin inhibitors
Author Model Result Comments
Niwa et al.81 2-stage chemical carcinogenesis
(DMBA/TPA) ± topical tacrolimus





marked decrease in CD4/CD8
ratio of draining lymph nodes;
c/w systemic immunosuppression
Jiang et al.82 2-stage chemical carcinogenesis (DMBA/TPA)
± topical tacrolimus (2 times weekly, 15 min
before TPA)
Decreased papillomas Marked decrease in tumorigenesis;
no mechanism sought; c/w topical
anti-inflammatory effects as protective
Yamamoto
et al.83
2-stage chemical carcinogenesis (DMBA/dithranol)
± topical ciclosporin (2 times weekly, 15 min
before dithranol)
Decreased papillomas Marked decrease in chemical carcinogenesis;
no mechanism sought; c/w topical
anti-inflammatory effects as protective
Yokota et al.84 2-stage chemical carcinogenesis (DMBA/TPA)
± topical (before TPA) vs. oral ciclosporin
Topical: decreased papillomas;
oral: increased carcinomas
Marked decrease in tumorigenesis;
c/w topical anti-inflammatory
effects as protective; c/w systemic
(oral) as immunosuppressive
DMBA, 7,12-dimethylbenz[a]anthracene; TPA, 12-O-tetradecanoylphorbol-13-acetate; c/w, consistent with.
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cancer risk, including malignancies of the skin.89 While sev-
eral of these cancers are virally associated [e.g. Epstein–Barr
virus (EBV) and lymphoproliferative lymphomas; human
papillomavirus and cutaneous SCC or cervical cancers], others
are not (e.g. thyroid, renal and lung carcinoma). Many of
these patients have also received systemic corticosteroids, and
thus it is difficult to separate the relative contributions of these
immunosuppressive medications in downregulation of the
antiviral and antitumour response. Nonetheless, systemic
absorption is a consideration of potential increased risk of
neoplasia in patients treated with TCI. Furthermore, several
cases of cutaneous T-cell lymphoma have also been reported
to progress or transform with use of oral calcineurin inhibi-
tors.90–100
While systemic absorption of TCI may be minimal, local
effects on immunosurveillance are possible, and in fact are
likely to be responsible for their ability to treat AD effectively.
These effects include inhibition of T-cell production of key
cytokines, such as interleukin-2 and interferon-c, presumed to
play roles in the antitumour response. One key distinction
from corticosteroids is that topical pimecrolimus does not
appear adversely to affect the number or function of LCs, the
presumed antigen-presenting cells of the epidermis.68 If LCs
are important in initiating antiviral and/or antitumour immune
responses, then this would suggest that topical pimecrolimus is
less likely to affect this pathway than corticosteroids.
In summary, TCI are not mutagenic or genotoxic (e.g.
potential initiators) or stimulators of proliferation (e.g. poten-
tial promoters). Therefore, the major theoretical consideration
for their role in carcinogenesis is with respect to inhibition of
immunosurveillance through systemic absorption or local
effects. Furthermore, there is experimental evidence that TCI
may inhibit cutaneous carcinogenesis under certain conditions,
perhaps through an anti-inflammatory effect on tumour-pro-
moting T cells. The precise effects of individual TCI on the
various components (e.g. ab and cd T cells, LCs and dendritic
cells, NK and NK/T cells) of local immunosurveillance, and
the contribution of such to risk of neoplasia, if any, remain to
be fully elucidated.
Question 6. What is the prevalence of neoplasia in the
population with and without atopic dermatitis?
Manuscripts identified in the initial literature search were
excluded from further review if they did not include human
subjects, were not in English, were individual case reports, or
were published only as abstracts. This yielded 375 manuscripts
published in the past 10 years. By an initial title review, 108
appeared to be on topic. Full abstracts of the 108 were
reviewed and by this review 50 were thought to be appropri-
ate. The full manuscript for each of these publications was
then read. Twelve were noted to be off topic or were rejected
because of the above exclusion criteria. An additional seven
publications were reviewed based on a review of the reference
sections of those publications that were fully reviewed. As a
result, 45 publications were evaluated more fully.101–144
There is no precise source for determining the rate of
malignancy in those who do not have AD. One publication
that estimates the rate of malignancy in the U.S.A. estimates
that the life-long risk of developing lymphoma for those
between birth and 39 years of age is 0Æ14% for men and
0Æ09% for women; for those between 40 and 59 years of age
is 0Æ46% for men and 0Æ31% for women; and for those
between 60 and 79 years of age is 0Æ32% for men and 1Æ00%
for women.101 Both this review and another noted that the
yearly rate of lymphoma had been increasing for several years
but has now levelled off.101,102 Unfortunately, it is impossible
to use Surveillance, Epidemiology and End Results data to dif-
ferentiate lymphoma in those with AD from lymphoma in
those who do not have AD, which is important to the study
question.
Seven studies specifically evaluated lymphoma and AD (or
eczema).103–109 These studies found odds ratios both above
and below 1Æ0. An estimated random effects meta-estimate of
these studies is 0Æ87 (95% confidence interval, CI: 0Æ4–11Æ3),
and the wide CI reflects the imprecision of this estimate. Of
note, three studies found that exposure to TS or systemic ster-
oids increased the risk of lymphoma.103–105 The incidence of
lymphoma in those with asthma, hay fever or both is not dif-
ferent from that in the general population.110
Several studies also evaluated the relationship between AD
and other types of malignancies including prostate cancer,
lung cancer, leukaemia, pancreatic cancer, brain tumours, skin
cancers, cervical cancer and myeloma.107–127 No association
between atopic illness and an increase in a specific malignancy
or malignancy in general could be demonstrated.
In summary, it does not appear that AD is likely to be asso-
ciated with any specific local or systemic malignancy. Further
study is needed before any firm conclusion is possible.
Question 7. What are the systemic side-effects of topical
therapies for atopic dermatitis?
The literature search yielded 602 titles of which 105 were
included, and five additional studies were identified through
hand searches.6,17,18,26–29,39,41–46,48–50,52,54–57,70,77,128–130,145–227
Inclusion criteria included: trials reported as full length, English-
language papers, a length of treatment of 2 weeks or longer,
and a sample size of 20 or more. Additionally, after the initial
search and review were completed, steroid studies were further
restricted to those performed since 1990. Case reports, letters,
editorials and nonsystematic reviews were excluded.
Corticosteroids were the most frequently studied agent, and
there were no reports of solid or haematological malignancy
or systemic infections found in any clinical trials (Table 9). It
should be noted that because corticosteroids have been pre-
scribed for so many years, doctors may not have felt com-
pelled to submit reports of malignancy. The same can be said
for other long-standing agents such as emollients, coal tar etc.
Conversely, the lack of reports may indicate that there is no
increased risk, or perhaps even a decreased risk with the use
of these agents.
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No malignancies have been reported in the published clini-
cal trials for the TCI tacrolimus and pimecrolimus; however,
11 and 13 cases, respectively, of lymphoma were sponta-
neously reported to the FDA and/or companies manufacturing
these products as of 1 March 2005 and data are on file with
the FDA, Novartis and Astellas. These spontaneous case reports
cannot be completely evaluated, but based on a review of the
information that is available, no case of an EBV-positive B-cell
lymphoma typical of an immunosuppression-related lym-
phoma has been reported. Whether these cases represent more
than would be expected in the general population of patients
with AD is impossible to determine as the exact exposure in
terms of patient number (the denominator needed for com-
parison of population-based incidence rates), dose and dura-
tion of treatment is not known.
Based on this systematic review of published clinical trials
and other sources of information, there are no data indicating
an increased risk of systemic side-effects or complications
(systemic infections or cancers) related to the use of the var-
ious topical medications in the treatment of AD (Table 9).
However, the length of many of the studies evaluating these
treatments was only a matter of weeks, and clearly was not
long enough to make any definite conclusions. At least with
TS, decades of open use in clinical practice with no documen-
ted relationship with systemic infections or systemic malig-
nancy provide reasonable confidence that these treatments are
unlikely to lead to systemic infections or cancers. TCI have
been the most intensely studied of the topical therapies for
AD with excellent short-term (weeks) and long-term (years)
safety as demonstrated in the highest form of evidence-based
randomized controlled trials. The spontaneous reports of lym-
phoma that have occurred outside of controlled trials cannot
be used to conclude that the use of these compounds can
result in systemic malignancy. Moreover, the types of malig-
nancies reported are not consistent with those expected to
arise with systemic exposure and the subsequent neoplasm
development related to immunosuppressant effects. However,
the currently available data do not allow one to exclude a risk
of malignancy with use of these compounds.
Discussion
AD is a common illness, yet, surprisingly, there are few qual-
ity data derived from prospective, population-based cohorts as
to its exact prevalence in the U.S. and other populations. The
best estimate based on the limited data available suggests an
approximately 15% lifetime prevalence of the disease. The
burden of illness of AD must be substantial given the preva-
lence of the disease and the impact this disease has on the
QoL of the patient and his/her family. The pathophysiology
of AD is similarly incompletely understood but probably
involves intrinsic or acquired abnormalities of the epidermal
barrier as well as defects in the regulation of immune and
inflammatory function. Whether genetic vs. environmental
factors predominate in the phenotypic expression of AD
remains unknown. Further identification of the pathophysiolo-
gical mechanisms of AD is critical to the development of novel
and targeted therapies for this disorder.
Table 9 Systematic review of the systemic side-effects (infection and neoplasia) of topical therapies for atopic dermatitis
Agent Studies Patients Age range Time on drug Results
Tacrolimusa 15 13 170 2–79 years 2 weeks–49 months No malignancy; spontaneous
reports of 11 lymphomas
+Steroid 4 2438 2–70 years 3 weeks–6 months No malignancy
Pimecrolimusb 5 844 3 months–adult 3 weeks–6 months No malignancy: spontaneous
reports of 13 lymphomas
+Steroid 7 3064 3 months–79 years 3 weeks–2 years No malignancy
Steroid 39 5325 6 months–88 years 2 weeks–6 months No malignancy; no systemic
infections
+Anti-infective 11 1202 1–84 years 13 days–1 month No systemic events
Emollients 3 267 18–55 years 2 weeks–3 months No systemic events
Tar 1 117 Mean 19 years Mean 30 days 7 malignancies reported
(< 17Æ3 expected): no
lymphoma
Doxepin 4 952 12–65 years 1 week No systemic effects
Anti-infectives 4 171 1–74 years 2–10 weeks No systemic events
Atopiclair 1 30 > 16 years 1 week No systemic events
Sodium
chromoglycolate
3 196 5 months–18 years 12 weeks No systemic events
Vitamin B12 1 49 18–70 years 8 weeks No systemic events
Ciclosporin 1 20 2–29 years 2 weeks No systemic events
Phosphodiesterase
inhibitors
2 117 18–64 years 2–4 weeks No systemic events
aSpontaneous reports of 11 lymphomas outside of clinical trials as of February 2005.
bSpontaneous reports of 13 lymphomas outside of clinical trials as of February 2005.
 2006 The Authors
Journal Compilation  2006 British Association of Dermatologists • British Journal of Dermatology 2007 156, pp203–221
Safety of therapies for atopic dermatitis, J. Callen et al. 213
The mechanism(s) of action of current topical therapies for
AD include those with little effect on immunosuppression
(emollients, doxepin etc.), broad effects (TS) and narrower
effects (TCI) and hypothetically these therapies could result in
systemic immunosuppression if drug dose and penetration
lead to significant absorption. Absorption with TS and TCI
does occur but varies widely depending on a variety of factors
including, but not limited to, disease state, dosage form and
the unique physiology of each patient. Local side-effects from
these agents are generally greater with TS than have been
demonstrated with TCI.
Most of the topical agents used in the treatment of AD do
not have systemic side-effects. There are systemic laboratory
alterations described with topical use of potent TS; however,
the clinical relevance of these laboratory changes remains
unknown. Evidence of systemic immunosuppression resulting
from topical application of calcineurin inhibitors has not been
documented. Systemic therapy with oral calcineurin inhibitors
does cause immunosuppression and has been accompanied by
the development of either cutaneous malignancies (SCC) or
EBV-related B-cell lymphomas as seen in chronically immuno-
suppressed transplant patients. An increased rate of EBV-related
B-cell lymphomas and/or cutaneous SCC would be expected
in patients with AD treated with TCI if sufficient absorption of
these agents altered immunosurveillance. However, neither
B-cell lymphomas, as described in patients immunosuppressed
by oral calcineurin inhibitors, nor an increase in epithelial
malignancies with TCI have been established. Spontaneous
cases of such tumours within this population have been
reported, but these reports are few in number and appear to
be within the occurrence rate expected in ‘normal’ popula-
tions. In summary, topical anti-inflammatory agents do not
appear to promote local cutaneous neoplasms, but the avail-
able data are limited and do not exclude the possibility of this
outcome. Given the enormous exposure of the population
with AD to these agents, the potential risk of malignancy must
be low given that significant findings would have been
observed, particularly for TS that have been widely used for
about half a century. In contrast, topical TCI have been avail-
able for only about 5 years, and therefore the clinical experi-
ence in understanding the potential for lymphoma is much
more limited. Clearly, investigation with longer-term trials is
required to delineate further this potential risk.
What is known with regard to the safety of topical therapies
for AD? (i) The prevalence of AD varies but is estimated to be
approximately 15% over the lifetime of an individual. (ii)
QoL is adversely affected by AD. (iii) The pathophysiology of
AD is multifactorial and involves abnormalities in barrier func-
tion and regulation of the inflammatory response. (iv) The
local side-effects of topical AD therapy are predominantly a
local cutaneous effect (erythema, itch, burn etc.), and infec-
tions are infrequent and are usually mild. (v) The systemic
exposure to TS and TCI is limited. The only well-documented
systemic side-effect of these agents is the effect of TS on the
HPA axis. (vi) The postulated mechanism of neoplasia in
patients treated with topical immunosuppressants is likely to
be an effect on immunosurveillance as genotoxicity and muta-
genicity do not occur. (vii) The incidence of neoplasia in
patients with AD is not increased vs. control patients in clini-
cal trials of any topical agents but large long-term controlled
trials are lacking in all.
Areas of uncertainty and unmet needs regarding the safety
of topical therapies for AD include the following: (i) the exact
point and lifetime prevalence of AD in various age groups and
ethnic populations with data that allow comparison among
populations; (ii) the magnitude of the effect of AD on an
individual’s QoL as well as that of the carer(s) when com-
pared with a normative population; (iii) whether improve-
ment in QoL with topical therapy for AD is clinically
meaningful; (iv) the exact abnormality in immune regulation
and barrier function responsible for the development of AD;
(v) the percentage of patients treated with TS and TCI who
have significant systemic exposure and an effect on systemic
immunological function, and how such patients be deter-
mined a priori so that alternative therapy can be used; (vi) the
incidence of neoplasia in patients with AD treated with TS and
TCI when compared with that of the general population.
The areas of uncertainty require resolution that can come
only from well-designed clinical trials, and certain issues, such
as the risk of immunosuppression-related malignancy asso-
ciated with use of topical therapies for AD, may never be
resolved. At this time, the evidence supports the continued
use of all of the currently available topical therapies for AD.
The data do not support the use of one therapy over another
based on any current evidence of difference in safety profiles
among the various topical therapies for AD. Although systemic
side-effects have occasionally been noted with TS but not with
TCI no direct head-to-head studies evaluating safety of these
two treatments have been performed. As such, the choice of
therapy for AD should be individualized based on the toler-
ability and efficacy of each agent. Until data are available that
support the consideration of other factors, such as safety, in
choosing therapy for AD, individualized tolerability and effi-
cacy should remain the most important factors in choice of
treatment for AD.
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